Apigenin Exerts Protective Effect and Restores Ovarian Function in Dehydroepiandrosterone Induced Polycystic Ovary Syndrome Rats: a Biochemical and Histological Analysis

Overview

Journal Ann Med

Publisher Informa Healthcare

Specialty General Medicine

Date 2022 Feb 14

PMID 35152800

Authors

Fangxin Peng

Yichuan Hu

Shu Peng

Ni Zeng

Lei Shi

Affiliations

Soon will be listed here.

Abstract

Background: Polycystic ovarian syndrome (PCOS) is one of the major causes encouraging the elevation of androgens, obesity along with menstrual complications. Here we study the effect of Apigenin in rat model of polycystic ovarian syndrome.

Methods: Female Sprague Dawley (SD) rats were treated with Dehydroepiandrosterone (DHEA) (6 mg/100g) opting the post-pubertal approach for developing rat model of polycystic ovarian syndrome, Metformin was used as standard. The treatments were given for 21 days along with coloproctological analysis. After the treatment regimen, the biochemical analysis was carried in plasma samples, whereas the ovaries were submitted for histopathological analysis.

Results: The treatment of DHEA resulted in disturbed lipid profile and anti-oxidant status along with increased weight, ovarian diameter and cysts in rats confirming the development of PCOS. However, treatment of Apigenin showed ameliorative effect by improving the lipid profile and anti-oxidant status, the treatment also normalised the body weight, reduced ovarian diameter, cysts and restored the healthy follicles compared to control rats. The treatment of Apigenin also suppressed the levels of oestradiol and testosterone compared to control group, also, levels of progesterone were increased in Apigenin treated group of rats. The treatment of Apigenin suppressed the levels of inflammatory cytokines TNF-α and IL-6. It was observed that the effect of Apigenin were to some extent parallel to standard drug Metformin.

Conclusion: The findings confirmed that Apigenin ameliorates the disturbed hormonal levels, lipid profile and antioxidant status in PCOS rats.

Citing Articles

Natural compounds in the management of polycystic ovary syndrome: a comprehensive review of hormonal regulation and therapeutic potential.

Yuan J, Li Z, Yu Y, Wang X, Zhao Y Front Nutr. 2025; 12:1520695.

PMID: 40008316 PMC: 11850276. DOI: 10.3389/fnut.2025.1520695.

Exploring the therapeutic potential of marjoram (Origanum majorana L.) in polycystic ovary syndrome: insights from serum metabolomics, network pharmacology and experimental validation.

Elfiky A, Ibrahim R, Khattab A, Kadry M, Ammar N, Shawky E BMC Complement Med Ther. 2025; 25(1):67.

PMID: 39984989 PMC: 11846456. DOI: 10.1186/s12906-025-04774-5.

Methanolic extract of wheatgrass ( L.) prevents BPA-induced disruptions in the ovarian steroidogenic pathway and alleviates uterine inflammation in Wistar rats.

Barman A, Ghosh A, Kar T, Chattopdhyay S 3 Biotech. 2024; 14(12):310.

PMID: 39600302 PMC: 11586330. DOI: 10.1007/s13205-024-04117-0.

Bridging gap in treatment of polycystic ovarian syndrome through drug repurposing: what we achieved and where we are?.

Kumbhar P, Chavan R, Darekar S, Kolekar K, Sequeira A, Vishwas S Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39520555 DOI: 10.1007/s00210-024-03578-7.

Apigenin as a Promising Agent for Enhancing Female Reproductive Function and Treating Associated Disorders.

Sirotkin A, Harrath A Biomedicines. 2024; 12(10).

PMID: 39457717 PMC: 11504338. DOI: 10.3390/biomedicines12102405.

References

Desai B, Maharjan R, Nampoothiri L . Aloe barbadensis Mill. formulation restores lipid profile to normal in a letrozole-induced polycystic ovarian syndrome rat model. Pharmacognosy Res. 2012; 4(2):109-15. PMC: 3326757. DOI: 10.4103/0974-8490.94736. View

De Bont R, Van Larebeke N . Endogenous DNA damage in humans: a review of quantitative data. Mutagenesis. 2004; 19(3):169-85. DOI: 10.1093/mutage/geh025. View

Marrano N, Spagnuolo R, Biondi G, Cignarelli A, Perrini S, Vincenti L . Effects of Extra Virgin Olive Oil Polyphenols on Beta-Cell Function and Survival. Plants (Basel). 2021; 10(2). PMC: 7913337. DOI: 10.3390/plants10020286. View

Kadowaki T, Yamauchi T . Adiponectin and adiponectin receptors. Endocr Rev. 2005; 26(3):439-51. DOI: 10.1210/er.2005-0005. View

Kraus S, Naor Z, Seger R . Intracellular signaling pathways mediated by the gonadotropin-releasing hormone (GnRH) receptor. Arch Med Res. 2001; 32(6):499-509. DOI: 10.1016/s0188-4409(01)00331-9. View

Franks S . Do animal models of polycystic ovary syndrome help to understand its pathogenesis and management? Yes, but their limitations should be recognized. Endocrinology. 2009; 150(9):3983-5. DOI: 10.1210/en.2009-0652. View

Zhang K, Song W, Li D, Jin X . Apigenin in the regulation of cholesterol metabolism and protection of blood vessels. Exp Ther Med. 2017; 13(5):1719-1724. PMC: 5443212. DOI: 10.3892/etm.2017.4165. View

Dunaif A . Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997; 18(6):774-800. DOI: 10.1210/edrv.18.6.0318. View

Ghowsi M, Khazali H, Sisakhtnezhad S . Evaluation of and mRNAs expressions in visceral and subcutaneous adipose tissues of polycystic ovarian rats and effects of resveratrol. Iran J Basic Med Sci. 2018; 21(2):165-174. PMC: 5811755. DOI: 10.22038/IJBMS.2017.24801.6167. View

10.

Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R . Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord. 2002; 26(7):883-96. DOI: 10.1038/sj.ijo.0801994. View

11.

Dandona P, Aljada A, Bandyopadhyay A . Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2003; 25(1):4-7. DOI: 10.1016/j.it.2003.10.013. View

12.

Verit F, Erel O . Oxidative stress in nonobese women with polycystic ovary syndrome: correlations with endocrine and screening parameters. Gynecol Obstet Invest. 2008; 65(4):233-9. DOI: 10.1159/000113046. View

13.

Burton G, Jauniaux E . Oxidative stress. Best Pract Res Clin Obstet Gynaecol. 2010; 25(3):287-99. PMC: 3101336. DOI: 10.1016/j.bpobgyn.2010.10.016. View

14.

Bogovich K, Richards J . Androgen biosynthesis in developing ovarian follicles: evidence that luteinizing hormone regulates thecal 17 alpha-hydroxylase and C17-20-lyase activities. Endocrinology. 1982; 111(4):1201-8. DOI: 10.1210/endo-111-4-1201. View

15.

Pisoschi A, Pop A . The role of antioxidants in the chemistry of oxidative stress: A review. Eur J Med Chem. 2015; 97:55-74. DOI: 10.1016/j.ejmech.2015.04.040. View

16.

Jung W . Protective effect of apigenin against oxidative stress-induced damage in osteoblastic cells. Int J Mol Med. 2014; 33(5):1327-34. DOI: 10.3892/ijmm.2014.1666. View

17.

Luo L, Huang J, Fu Y, Xu J, Qian Y . Effects of tea polyphenols on ovarian development in rats. J Endocrinol Invest. 2009; 31(12):1110-8. DOI: 10.1007/BF03345661. View

18.

Gonzalez F, Rote N, Minium J, Kirwan J . Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2005; 91(1):336-40. DOI: 10.1210/jc.2005-1696. View

19.

Sies H . Oxidative stress: from basic research to clinical application. Am J Med. 1991; 91(3C):31S-38S. DOI: 10.1016/0002-9343(91)90281-2. View

20.

Su T, Huang C, Yang C, Jiang T, Su J, Chen M . Apigenin inhibits STAT3/CD36 signaling axis and reduces visceral obesity. Pharmacol Res. 2019; 152:104586. DOI: 10.1016/j.phrs.2019.104586. View